Every 8-K that Surgery Partners, Inc. (SGRY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SGRY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SGRY filings page.
Surgery Partners, Inc. (SGRY) completed the sale of its ownership interests in Mountain View Hospital, Idaho Falls Community Hospital, and related subsidiaries in Idaho Falls (the “Disposed Business”) to Intermountain Health on September 14, 2026. The company reports aggregate consideration of approximately $796.6 million, including payment for terminating its management agreement with Mountain View Hospital, with total consideration subject to closing and post‑closing adjustments.
Net cash consideration at closing is estimated at $586.5 million, and Surgery Partners intends to use the proceeds primarily to pay down debt, which it expects will reduce balance sheet leverage under its credit agreement. Pro forma financials show how results would have looked if the transaction had occurred earlier, with 2025 revenues decreasing from $3.31 billion historically to $2.59 billion on a pro forma basis and GAAP net loss attributable to Surgery Partners widening from $77.9 million to $108.2 million. Updated 2026 guidance calls for full‑year revenue of $3.08–$3.18 billion and Adjusted EBITDA of at least $489 million, with pro forma revenue of $2.60–$2.67 billion and pro forma Adjusted EBITDA of at least $414 million excluding the Idaho Falls facilities.
Surgery Partners, Inc. reported second quarter 2026 revenue of $848.9 million, up 2.7% year over year, with same-facility revenue rising 5.0% driven by a 4.8% increase in revenue per case and a modest 0.3% increase in same-facility cases. Adjusted EBITDA was $125.2 million versus $129.0 million a year ago, an Adjusted EBITDA margin of 14.7%. Net loss attributable to Surgery Partners, Inc. widened to $15.0 million, or $(0.12) per diluted share.
For the first half of 2026, revenue grew 3.6% to $1,659.8 million and Adjusted EBITDA was $227.5 million. The company ended June 30, 2026 with $216.7 million of cash, $617.8 million of undrawn revolver capacity and a total net debt to EBITDA ratio of about 4.4x. Management reaffirmed full-year 2026 guidance for revenue of $3.35–$3.45 billion and Adjusted EBITDA of at least $530 million, excluding the pending divestiture of its Idaho Falls market, which is expected to improve cash conversion and support deleveraging.
Surgery Partners, Inc. is pursuing a sale of its ownership interests in Mountain View Hospital, LLC and Idaho Falls Community Hospital, LLC to Intermountain Health. The combined Idaho Falls facilities are valued at approximately $1.15 billion, with total consideration to Surgery Partners of approximately $795 million, expected to result in substantial cash proceeds subject to customary purchase price adjustments. Signature pages to Securities Purchase Agreements have been placed into escrow, and completion depends on Mountain View Hospital physician member and governing board approvals, accuracy of representations, regulatory clearances including Hart-Scott-Rodino waiting periods, and key third-party consents.
The company characterizes this as a major step in its portfolio optimization strategy, sharpening its focus on ambulatory surgery centers while physician ownership of Mountain View Hospital remains unchanged. Excluding the impact of the transaction, Surgery Partners reaffirms its 2026 outlook for revenues of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million. The Idaho Falls facilities together have 126 beds and employ over 150 physicians, offering nine surgical specialties and additional services including oncology, emergency, ICU, and neonatology.
Surgery Partners, Inc. reported the results of its annual shareholder meeting. As of the April 8, 2026 record date, 130,798,102 common shares were outstanding and entitled to vote. Stockholders re-elected Class II directors Devin O'Reilly, Brent Turner, and Laura L. Forese, M.D., to serve until the 2029 annual meeting.
Shareholders also approved, on a non-binding advisory basis, the company’s executive compensation program, with 111,639,092 votes for, 2,018,777 against, and 15,275 abstentions, along with 6,243,195 broker non-votes. In addition, stockholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 119,828,741 votes for, 62,950 against, and 24,648 abstentions.
Surgery Partners, Inc. reported first quarter 2026 revenue of $810.9 million, up 4.5% from the prior year, driven by 4.4% same-facility revenue growth on modest 0.6% case growth and a 3.8% increase in revenue per case. Adjusted EBITDA was $102.3 million, slightly below $103.9 million a year earlier, while net loss attributable to Surgery Partners narrowed to $35.9 million, or $(0.28) per basic and diluted share. The company ended March 31, 2026 with $182.3 million of cash and cash equivalents and $666.1 million of available borrowing capacity, with total net debt to EBITDA of roughly 4.3x. Management reaffirmed full-year 2026 guidance for revenue of $3.35–$3.45 billion and Adjusted EBITDA of at least $530 million, implying organic Adjusted EBITDA growth of at least 4.2% versus 2025 normalized levels.
Surgery Partners, Inc. reported higher 2025 revenue but remained unprofitable while setting cautious 2026 goals and launching a new share repurchase program.
Full-year 2025 revenue rose 6.2% to $3.31 billion, with same-facility revenue up 4.9% driven by 3.4% same-facility case growth and a 1.4% increase in revenue per case. Adjusted EBITDA increased 3.5% to $526.2 million, but net loss attributable to Surgery Partners was $77.9 million, though this improved from a larger loss in 2024.
Fourth-quarter 2025 revenue grew 2.4% to $885.0 million, while Adjusted EBITDA slipped 4.2% to $156.9 million, reflecting margin pressure. The company ended 2025 with $239.9 million of cash and total net debt to EBITDA of about 4.3x under its credit agreement.
For 2026, management targets Adjusted EBITDA of at least $530 million and revenue between $3.35 billion and $3.45 billion, implying modest organic growth after factoring provider tax and tariff headwinds. The board also authorized a new share repurchase program of up to $200 million of common stock, signaling confidence while the company focuses on higher-acuity procedures, portfolio optimization and reducing leverage.
Surgery Partners, Inc., through its wholly-owned subsidiary Surgery Center Holdings, Inc., issued an additional $425.0 million aggregate principal amount of 7.250% Senior Notes due 2032. The new notes were issued under a Third Supplemental Indenture dated December 16, 2025, with Wilmington Trust, National Association as trustee.
The additional notes have the same terms as the existing $800.0 million 7.250% Senior Notes due 2032 and will be treated as a single series with those notes under the same CUSIP number. Any notes issued pursuant to Regulation S will trade separately under a different CUSIP number until 40 days after the issue date before becoming fungible for U.S. federal income tax purposes with the existing and other new notes.
Surgery Partners, Inc., through its subsidiary Surgery Center Holdings, Inc., agreed to issue and sell $425.0 million in aggregate principal amount of 7.250% senior unsecured notes due 2032. These notes are being sold under a purchase agreement with Barclays Capital Inc., acting as representative of the initial purchasers. The company plans to use the net proceeds for general corporate purposes, including repaying outstanding borrowings under its revolving credit facility. The completion of this notes offering is described as being subject to market and other conditions, meaning it is not yet finalized. Surgery Partners also announced the pricing of the notes in a press release dated December 11, 2025.
Surgery Partners, Inc. reported that its wholly owned subsidiary, Surgery Center Holdings, Inc., intends to offer $425.0 million of additional 7.250% Senior Notes due 2032. The notes are expected to be offered in a private transaction conducted under Rule 144A and Regulation S.
The company stated that net proceeds are expected to be used for general corporate purposes, which may include repaying outstanding borrowings under its revolving credit facility. Surgery Partners also cautioned that the offering may not be completed on the terms or in the amounts anticipated, or at all, and referenced existing risk factors in its annual and quarterly reports.
Surgery Partners, Inc. announced the appointment of Justin Oppenheimer as Chief Operating Officer and National Group President, effective January 1, 2026. He joins from the Hospital for Special Surgery, where he spent a decade in leadership roles including Chief Strategy Officer and Chief Operating Officer.
Oppenheimer serves on the board of Urban Dove, a New York-based charter school management organization, and holds a B.A. in political economy from Princeton University and an MBA from Harvard Business School. The company referenced his employment agreement as Exhibit 10.1, dated October 27, 2025.
Surgery Partners, Inc. (SGRY) furnished an 8-K announcing results for the three and nine months ended September 30, 2025. The company issued a press release, attached as Exhibit 99.1, detailing the period’s performance.
The disclosure under Item 2.02 is provided pursuant to General Instruction B.2 and is deemed furnished, not filed. The release includes non-GAAP financial measures with reconciliations to the most comparable GAAP measures.
Surgery Partners, Inc. reported that Harrison R. Bane, its National Group President, has decided to resign from his current role, effective October 3, 2025. The company states that Mr. Bane’s resignation is not due to any disagreement with Surgery Partners on operations, policies, or practices, indicating this is a personal or career decision rather than a dispute with the company.
Surgery Partners, Inc. entered into a Second Amendment to its credit agreement on August 13, 2025 that restructures its existing debt facilities. The amendment provides a new tranche of term loans totaling $1,383 million that refinances in full the prior term loans and also refinances the existing revolving credit commitments and outstanding revolving loans.
The 2025 Refinancing Term Loans mature on December 19, 2030 and the refinanced revolving loans mature on December 19, 2028. Interest will accrue at either Term SOFR + 2.50% or an alternate base rate plus 1.50%. The term loans amortize in equal quarterly installments of 0.25% of original principal beginning with the quarter ending September 30, 2025. Voluntary prepayments are permitted without penalty except a 1.00% call premium for certain repricing events within six months. The full amendment is filed as Exhibit 10.1.
Surgery Partners, Inc. (Nasdaq: SGRY) filed a Form 8-K dated 5 Aug 2025. Under Item 2.02, the Company states it has furnished—not filed—a press release (Exhibit 99.1) that outlines results for the three- and six-month periods ended 30 Jun 2025. No numerical performance data are included in the 8-K itself. The filing notes that any non-GAAP measures discussed in the release are reconciled to the most comparable GAAP figures within that exhibit. Pursuant to General Instruction B.2, the furnished information is not subject to Section 18 liability and is not incorporated by reference into other SEC filings. Exhibit 104 provides the Inline XBRL cover page tag set.